

## ICMR licenses nine breakthrough health technologies to industry partners

04 September 2025 | News

## A major step toward Viksit Bharat in healthcare as public research meets private sector strength



In a landmark moment for India's healthcare innovation ecosystem, the Indian Council of Medical Research (ICMR) licensed nine cutting-edge technologies to industry partners under its *Medical Innovations— Patent Mitra* initiative, at Bharat Mandapam, New Delhi.

During the inaugural session of the India MedTech Expo 2025, the ceremony resulted in 17 licensing deals for innovations developed by various ICMR institutes in the areas of infectious disease diagnostics, immunodiagnostics, and vaccine development.

Technologies licensed during the ceremony include:

- Multistage Malaria Vaccine licensed to Indian Immunologicals Limited, Techinvention Lifecare Private Limited, Panacea Biotec Limited, Biological E Limited, and Zydus Lifesciences
- Diagnostic ELISA kits for the detection of IgM antibodies against Japanese Encephalitis virus, licensed to Diatek Healthcare Private Limited and Medsource Ozone Biomedicals Private Limited
- Diagnostic ELISA kits for the detection of IgM antibodies against Dengue virus, licensed to Diatek Healthcare Private Limited and Medsource Ozone Biomedicals Private Limited
- Diagnostic ELISA kits for the detection of IgM antibodies against Chikungunya virus, licensed to Diatek Healthcare Private Limited; Medsource Ozone Biomedicals Private Limited; and Matrix Labs Private Limited

- The AFuPEPLISA immunodiagnostic kit for detecting antibodies to Aspergillus fumigatus in patient sera, licensed to Medsource Ozone Biomedicals Private Limited
- A colorimetric isothermal (LAMP) assay for rapid detection of Monkeypox virus, licensed to SmartQR Technologies
  Private Limited
- A colorimetric RT-LAMP (isothermal) assay for rapid detection of Nipah virus, also licensed to SmartQR Technologies Private Limited
- A novel glycoconjugate Salmonella vaccine licensed to Biological E Limited
- A novel oral Shigella vaccine based on Multi-Serotype Outer Membrane Vesicles (MOMVs) licensed to Biological E Limited

This initiative ensures that life-saving tools developed through public research are available to communities across India. The manufacturing strength and distribution networks of industry partners will be instrumental in expanding the reach and impact of these technologies. This public-private partnership is a powerful catalyst for advancing India's healthcare goals and plays a vital role in the journey toward achieving the vision of Viksit Bharat by 2047.